-+ 0.00%
-+ 0.00%
-+ 0.00%

Barrington Research Maintains Outperform on Haemonetics, Lowers Price Target to $86

Benzinga·08/08/2025 12:20:12
Listen to the news
Barrington Research analyst Michael Petusky maintains Haemonetics (NYSE:HAE) with a Outperform and lowers the price target from $95 to $86.